NVO - Novo Nordisk A/S

NYSE - NYSE Delayed price. Currency in USD
Show:
Income statement
Balance sheet
Cash flow
Annual

Income statement

Currency in DKK. All numbers in thousands
Breakdown
ttm
31/12/2019
31/12/2018
31/12/2017
31/12/2016
Total revenue
126,605,000
122,021,000
111,831,000
111,696,000
111,780,000
Cost of revenue
20,742,000
20,088,000
17,617,000
17,632,000
17,183,000
Gross profit
105,863,000
101,933,000
94,214,000
94,064,000
94,597,000
Operating expenses
Research development
15,319,000
14,220,000
14,805,000
14,014,000
14,563,000
Selling general and administrative
36,490,000
35,830,000
33,313,000
32,124,000
32,339,000
Total operating expenses
51,317,000
49,450,000
46,966,000
45,097,000
46,165,000
Operating income or loss
54,546,000
52,483,000
47,248,000
48,967,000
48,432,000
Interest expense
488,000
220,000
85,000
90,000
65,000
Total other income/expenses net
-
-3,494,000
473,000
-198,000
-536,000
Income before tax
50,352,000
48,553,000
47,615,000
48,680,000
47,798,000
Income tax expense
9,949,000
9,602,000
8,987,000
10,550,000
9,873,000
Income from continuing operations
40,403,000
38,951,000
38,628,000
38,130,000
37,925,000
Net income
40,403,000
38,951,000
38,628,000
38,130,000
37,925,000
Net income available to common shareholders
40,403,000
38,951,000
38,628,000
38,130,000
37,925,000
Basic EPS
-
16.41
15.96
15.42
14.99
Diluted EPS
-
16.38
15.93
15.39
14.96
Basic average shares
-
2,374,299
2,419,603
2,473,218
2,529,945
Diluted average shares
-
2,378,658
2,424,417
2,478,093
2,534,729
EBITDA
-
54,434,000
51,625,000
51,952,000
51,056,000
By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more